Bristol Megace

Patent infringement complaint against Par Pharmaceutical regarding megestrol oral formulation dismissed Dec. 14 by the New York Southern District Court. Par's counterclaims for patent invalidity, unfair competition and interference remain. Par received a tentative approval in October and anticipates marketing no later than February 2002